Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.35 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7707823 | 0.91 | ALOX5 (0.44) | ALOX5SMN1; SMN2LMNAPTGESPDE3B | |
| SCHEMBL8551585 | 0.90 | SMN1; SMN2 (0.48) | ALOX5SMN1; SMN2LMNAPTGESPDE3B | |
| SCHEMBL8551861 | 0.89 | ALOX5 (0.41) | ALOX5SMN1; SMN2LMNAPTGESPDE3B | |
| SCHEMBL7424550 | 0.88 | ALOX5 (0.39) | ALOX5SMN1; SMN2LMNAPTGESPDE3B | |
| SCHEMBL8557456 | 0.84 | LMNA (0.48) | ALOX5SMN1; SMN2LMNAPTGESPDE3B | |
| SCHEMBL8555588 | 0.82 | SMN1; SMN2 (0.47) | ALOX5SMN1; SMN2LMNAPTGESPDE3B | |
| SCHEMBL8555747 | 0.82 | PLK1 (0.39) | ALOX5SMN1; SMN2LMNAPDE3BPDE3A | |
| SCHEMBL8553605 | 0.81 | ALOX5 (0.48) | ALOX5SMN1; SMN2LMNAPTGESPDE3B | |
| SCHEMBL8554263 | 0.81 | ALOX5 (0.39) | ALOX5SMN1; SMN2LMNAPTGESPDE3B | |
| SCHEMBL6930961 | 0.81 | ALOX5 (0.39) | ALOX5SMN1; SMN2LMNAPTGESPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1624893-A2 | INHIBITORS OF PHOSPHODIESTERASES IN INFERTILITY | Applied Research Systems ARS Holding N.V. (AN) | 2006-02-15 | — | — | EP | claimed |
| WO-2004087211-A2 | INHIBITORS OF PHOSPHODIESTERASES IN INFERTILITY | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-10-14 | — | — | WO | claimed |
| JP-2003525845-A | — | — | 2003-09-02 | — | — | JP | claimed |
| EP-1027054-A4 | LOCAL ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | VIVUS INC (US) | 2002-11-04 | — | — | EP | claimed |
| EP-1237577-A2 | TRANSMUCOSAL COMPOSITION CONTAINING A PHOSPHODIESTERASE INHIBITOR FOR THE TREATMENT OF ERECTILE DYSFUNCTION | Vivus, Inc. (US) | 2002-09-11 | — | — | EP | claimed |
| WO-2001070211-A2 | L-ARGININE AND PHOSPHODIESTERASE (PDE) INHIBITOR SYNERGISM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-09-27 | — | — | WO | claimed |
| WO-2001041807-A2 | TRANSMUCOSAL COMPOSITION CONTAINING A PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | VIVUS, INC. (US) | 2001-06-14 | — | — | WO | claimed |
| EP-1027054-A1 | LOCAL ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | Vivus, Inc. (US) | 2000-08-16 | — | — | EP | claimed |
| WO-1999021558-A2 | LOCAL ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | VIVUS, INC. (US) | 1999-05-06 | — | — | WO | claimed |
| WO-2018132371-A2 | METHODS AND COMPOSITIONS FOR TREATING PULMONARY HYPERTENSION | UNITED THERAPEUTICS CORPORATION (US) | 2018-07-19 | — | — | WO | disclosed |
| WO-2013067309-A1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONIST COMPOUNDS | XION PHARMACEUTICAL CORPORATION (US) | 2013-05-10 | — | — | WO | disclosed |
| EP-2512479-A1 | METHODS AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE | Exodos Life Sciences Limited Partnership (US) | 2012-10-24 | — | — | EP | disclosed |
| EP-2401279-A1 | 1, 4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | Vantia Limited (GB) | 2012-01-04 | — | — | EP | disclosed |
| WO-2011075655-A1 | METHODS AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE | EXODOS LIFE SCIENCES LIMITED PARTNERSHIP (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2002019213-A2 | METHOD FOR TREATMENT OF MIGRAINE USING PDE5 INHIBITORS | LILLY ICOS LLC (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2002017927-A1 | METHOD FOR TREATING ERECTILE DYSFUNCTION AND INCREASING LIBIDO IN MEN | UNIMED PHARMACEUTICALS, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2001070211-A2 | L-ARGININE AND PHOSPHODIESTERASE (PDE) INHIBITOR SYNERGISM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-09-27 | — | — | WO | disclosed |
| EP-1027057-A1 | TREATMENT OF FEMALE SEXUAL DYSFUNCTION | Asivi, LLC (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999021562-A1 | TREATMENT OF FEMALE SEXUAL DYSFUNCTION | ASIVI, LLC (US) | 1999-05-06 | — | — | WO | disclosed |
| EP-0820441-A1 | INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-01-28 | — | — | EP | disclosed |